GICS Sector : Healthcare
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors.The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness.Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications.
Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
Nov -12
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
Nov -10
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition
Nov -03
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee
Sep -03
Lyell Immunopharma Announces Participation in September Investor Conferences
Sep -02
Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2025
Aug -12
Lyell Immunopharma Announces up to $100 Million Equity Private Placement
Jul -25
Lyell: 'Hold' Rating Based On Phase 3 LYL314 LBCL Treatment Program Advancement
Jul -22
Increasing adoption of personalized cancer treatments, advancements in T-cell therapy, and growing demand for targeted cancer therapies drive the growth of Lyell Immunopharma's T-Cell Therapies.
A personalized neoantigen-based immunotherapy for the treatment of solid tumors
A cell-based immunotherapy for the treatment of lymphoma
A personalized neoantigen-based immunotherapy for the treatment of solid tumors
A T cell receptor-based immunotherapy for the treatment of various cancers
The threat of substitutes for Lyell Immunopharma, Inc. is medium due to the presence of alternative treatments and therapies for cancer and autoimmune diseases.
The bargaining power of customers for Lyell Immunopharma, Inc. is low due to the lack of negotiating power of individual patients and the high demand for innovative cancer and autoimmune disease treatments.
The bargaining power of suppliers for Lyell Immunopharma, Inc. is medium due to the presence of multiple suppliers for raw materials and equipment, but the high demand for specialized components.
The threat of new entrants for Lyell Immunopharma, Inc. is high due to the growing interest in immunotherapy and the increasing number of biotech startups and pharmaceutical companies entering the market.
The intensity of rivalry for Lyell Immunopharma, Inc. is high due to the presence of established pharmaceutical companies and biotech firms, as well as the increasing competition for market share and talent.
| Value | |
|---|---|
| Debt Weight | 8.80% |
| Debt Cost | 3.95% |
| Equity Weight | 91.20% |
| Equity Cost | 1.19% |
| WACC | 1.44% |
| Leverage | 9.64% |
Value: 7.8
Growth: 3.3
Quality: 4.3
Yield: 0.0
Momentum: 9.5
Volatility: 1.0
1-Year Total Return ->
Value: 9.8
Growth: 6.1
Quality: 2.4
Yield: 0.0
Momentum: 5.0
Volatility: 0.0
1-Year Total Return ->
Value: 6.8
Growth: 6.9
Quality: 3.8
Yield: 0.0
Momentum: 2.5
Volatility: 1.7
1-Year Total Return ->
Value: 8.4
Growth: 6.0
Quality: 3.8
Yield: 0.0
Momentum: 0.5
Volatility: 1.0
1-Year Total Return ->
Value: 7.6
Growth: 1.0
Quality: 4.7
Yield: 0.0
Momentum: 5.5
Volatility: 0.7
1-Year Total Return ->
Value: 8.6
Growth: 5.4
Quality: 3.8
Yield: 0.0
Momentum: 0.5
Volatility: 0.7
1-Year Total Return ->